FDA granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit as the first commercially available test to specifically detect percentage of neutralization antibodies in people who have been previously infected or post vaccination.
 

Demonstrated 100% Sensitivity and 100% Specificity rate as compared to other antibody testing kits.

Comparison of numerical results (% Neutralization) will help determine how the immune response develops in an individual and persists over time.  

Measuring the abundance of neutralizing antibodies is one of the key parameters for evaluating SARS-CoV-2 vaccines.

​

​

​

​